Literature DB >> 15968242

Current diagnosis and treatment of pancreatic cancer in China.

Xiaozhong Guo1, Zhongmin Cui.   

Abstract

In China, morbidity and mortality for pancreatic cancer differs from that in most Western countries. Pancreatic cancer is the sixth leading cause of death from malignant disease in China, with an overall cumulative 5-year survival rate of 1% to 3%. Pancreatic cancer has the highest incidence in Shanghai (7.21/100,000) and the lowest (0.47/100,000) in the Hunan Province. As in the Western world, the main reason for the poor outcome of patients with pancreatic cancer is the late establishment of the diagnosis. Pancreatic cancer is seldom detected in early disease stages, and until now, the process of cancer initiation, progression, and formation of metastasis is not sufficiently understood. In this article, we reviewed recent data on patients in China with pancreatic cancer and obtained the most updated information on the different aspects of oncologic research, including epidemiology, molecular biology, diagnosis, and treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968242     DOI: 10.1097/01.mpa.0000168220.97967.d1

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  33 in total

1.  On pancreatic cancer screening by magnetic resonance imaging with the recent evidence by Del Chiaro and colleagues.

Authors:  Yì-Xiáng J Wáng; Jing-Shan Gong; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

2.  Construction of targeted plasmid vector pcDNA3.1-Egr.1p-p16 and its expression in pancreatic cancer JF305 cells induced by radiation in vitro.

Authors:  Hong-Bing Ma; Xi-Jing Wang; Zheng-Li Di; Hui Xia; Zheng Li; Jie Liu; Jie Ma; Hua-Fen Kang; Cong-Mei Wu; Ming-Hua Bai
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

3.  Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.

Authors:  Dong-Sheng Huang; Zhaohui Wang; Xu-Jun He; Bill H Diplas; Rui Yang; Patrick J Killela; Qun Meng; Zai-Yuan Ye; Wei Wang; Xiao-Ting Jiang; Li Xu; Xiang-Lei He; Zhong-Sheng Zhao; Wen-Juan Xu; Hui-Ju Wang; Ying-Yu Ma; Ying-Jie Xia; Li Li; Ru-Xuan Zhang; Tao Jin; Zhong-Kuo Zhao; Ji Xu; Sheng Yu; Fang Wu; Junbo Liang; Sizhen Wang; Yuchen Jiao; Hai Yan; Hou-Quan Tao
Journal:  Eur J Cancer       Date:  2015-04-02       Impact factor: 9.162

4.  Polymorphisms in UGT2B4 and susceptibility to pancreatic cancer.

Authors:  Xu Che; Dianke Yu; Zongyong Wu; Jianwei Zhang; Yintai Chen; Yaling Han; Chenfeng Wang; Jun Qi
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  ABO blood type, diabetes and risk of gastrointestinal cancer in northern China.

Authors:  Yan Gong; Yun-Sheng Yang; Xiao-Mei Zhang; Ming Su; Jean Wang; Jin-Dong Han; Ming-Zhou Guo
Journal:  World J Gastroenterol       Date:  2012-02-14       Impact factor: 5.742

6.  MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer.

Authors:  Kemin Wu; Guohuang Hu; Xin He; Peng Zhou; Jian Li; Bin He; Weijia Sun
Journal:  Pathol Oncol Res       Date:  2013-05-09       Impact factor: 3.201

7.  Direct in vivo injection of 131I-GMS and its distribution and excretion in rabbit.

Authors:  Yu Ma; Yi Wan; Dong-Hui Luo; Li-Geng Duan; Lin Li; Chuan-Qin Xia; Xiao-Li Chen
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

8.  Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells.

Authors:  Meiying Li; Xuejun Yu; Hui Guo; Limei Sun; Aijun Wang; Qiji Liu; Xiuwen Wang; Jisheng Li
Journal:  Tumour Biol       Date:  2013-11-12

9.  Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer.

Authors:  Er-Jun Pang; Rui Yang; Xi-bo Fu; Ye-fu Liu
Journal:  Tumour Biol       Date:  2014-12-08

10.  CTNND1 755 T>G Promoter Polymorphism and Risk of Pancreatic Carcinoma in Chinese.

Authors:  Wei Wang; Yang Fei; Sheng-Li Liu
Journal:  J Clin Lab Anal       Date:  2016-08-27       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.